Jesus Vera, MD
Cardiovascular Disease · Fullerton, CANPI 1780621821
Payments from drug & device makers
Across 272 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$564
- Amgen$552
- Pfizer$514
- Boehringer Ingelheim$403
- Sanofi-aventis U.S. LLC$369
- E.r. Squibb & Sons, L.L.C.$365
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,752100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 60 | $564 |
| Amgen | 34 | $552 |
| Pfizer | 39 | $514 |
| Boehringer Ingelheim | 22 | $403 |
| Sanofi-aventis U.S. LLC | 17 | $369 |
| E.r. Squibb & Sons, L.L.C. | 29 | $365 |
| Shockwave Medical, Inc | 3 | $312 |
| Abiomed | 4 | $301 |
| Boston Scientific | 7 | $178 |
| Abbott | 3 | $168 |
| Medtronic | 6 | $158 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $145 |
| Johnson & Johnson | 8 | $126 |
| Merck | 7 | $117 |
| Kestra Medical Technology Services, Inc. | 5 | $90 |
| AstraZeneca | 5 | $80 |
| Astellas Pharma US Inc | 3 | $74 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Impulse Dynamics (USA) Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,774 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 525 | $597,831 |
| Repatha SureclickEvolocumab | 309 | $299,559 |
| XareltoRivaroxaban | 214 | $241,469 |
| EntrestoSacubitril/Valsartan | 148 | $170,948 |
| BrilintaTicagrelor | 75 | $52,125 |
| Praluent PenAlirocumab | 55 | $45,911 |
| MultaqDronedarone Hcl | 18 | $33,803 |
| JardianceEmpagliflozin | 22 | $29,704 |
| FarxigaDapagliflozin Propanediol | 15 | $10,844 |
| Atorvastatin Calcium | 680 | $8,669 |
| Propafenone Hcl ErPropafenone Hcl | 29 | $7,945 |
| Metoprolol Succinate | 495 | $7,433 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 16 | $6,616 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $4,637 |
| Losartan Potassium | 388 | $4,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $514 | $597,831525 claims |
| Johnson & JohnsonXarelto | $126 | $241,469214 claims |
| NovartisEntresto | $564 | $170,948148 claims |
| AstraZenecaBrilinta, Farxiga | $80 | $62,96990 claims |
| Sanofi-aventis U.S. LLCMultaq | $369 | $33,80318 claims |
| Boehringer IngelheimJardiance | $403 | $29,70422 claims |
| Esperion Therapeutics, Inc.Nexlizet | $19 | $4,63712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Fullerton
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.